Seminoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
| (7 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Seminoma}} | {{Seminoma}} | ||
{{CMG}}{{AE}}{{ | {{CMG}}{{AE}}{{S.G.}} | ||
==Overview== | ==Overview== | ||
Effective measures for the secondary [[Prevention (medical)|prevention]] of seminoma include regular follow-ups for every 2–6 months for the first 3 years and every 6–12 months after 3 years. Tests are often part of follow-up care include [[Blood test|blood tests]] to check [[tumor marker|serum tumor marker levels]], [[Chest X-ray|chest x-rays]], and [[Computed tomography|CT scans]] of the [[abdomen]] and [[pelvis]]. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
Effective measures for the secondary prevention of seminoma include: | *Effective measures for the secondary prevention of seminoma include:<ref name="pmid21819630">{{cite journal |vauthors=Boujelbene N, Cosinschi A, Boujelbene N, Khanfir K, Bhagwati S, Herrmann E, Mirimanoff RO, Ozsahin M, Zouhair A |title=Pure seminoma: a review and update |journal=Radiat Oncol |volume=6 |issue= |pages=90 |date=August 2011 |pmid=21819630 |pmc=3163197 |doi=10.1186/1748-717X-6-90 |url=}}</ref><ref name="PalyEfstathiou20132">{{cite journal|last1=Paly|first1=Jonathan J.|last2=Efstathiou|first2=Jason A.|last3=Hedgire|first3=Sandeep S.|last4=Chung|first4=Peter W.M.|last5=O’Malley|first5=Martin|last6=Shah|first6=Anand|last7=Bekelman|first7=Justin E.|last8=Harisinghani|first8=Mukesh|last9=Shipley|first9=William U.|last10=Zietman|first10=Anthony L.|last11=Beard|first11=Clair|title=Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields|journal=Radiotherapy and Oncology|volume=106|issue=1|year=2013|pages=64–68|issn=01678140|doi=10.1016/j.radonc.2012.12.002}}</ref> | ||
** Follow-up [[Patient|patients]]: | |||
***Every 2–6 months for the first 3 years | |||
***Every 6–12 months after 3 years | |||
**Follow-up test include: | |||
*:*[[Blood test|Blood tests]] to check [[tumor marker|serum tumor marker levels]] to see if they returned to normal after treatment | |||
=== | *:*[[Chest X-ray|Chest x-rays]] to check if cancer has [[Metastasis|metastasized]] to the [[Lung|lungs]] | ||
*:*[[Computed tomography|CT scans]] of the [[abdomen]] and [[pelvis]] to look for any residual [[disease]] or that has [[Metastasis|metastasized]] elsewhere | |||
* | |||
* | |||
* | |||
* | |||
:*Blood tests to check [[tumor marker|serum tumor marker levels]] to see if they returned to normal after treatment | |||
:*Chest x-rays to check if cancer has metastasized to the lungs | |||
:*CT scans of the abdomen and pelvis to look for any residual disease or that has metastasized elsewhere | |||
==References== | ==References== | ||
Latest revision as of 15:54, 6 May 2019
|
Seminoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Seminoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Seminoma secondary prevention |
|
Risk calculators and risk factors for Seminoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
Effective measures for the secondary prevention of seminoma include regular follow-ups for every 2–6 months for the first 3 years and every 6–12 months after 3 years. Tests are often part of follow-up care include blood tests to check serum tumor marker levels, chest x-rays, and CT scans of the abdomen and pelvis.
Secondary Prevention
- Effective measures for the secondary prevention of seminoma include:[1][2]
- Follow-up patients:
- Every 2–6 months for the first 3 years
- Every 6–12 months after 3 years
- Follow-up test include:
- Blood tests to check serum tumor marker levels to see if they returned to normal after treatment
- Chest x-rays to check if cancer has metastasized to the lungs
- CT scans of the abdomen and pelvis to look for any residual disease or that has metastasized elsewhere
- Follow-up patients:
References
- ↑ Boujelbene N, Cosinschi A, Boujelbene N, Khanfir K, Bhagwati S, Herrmann E, Mirimanoff RO, Ozsahin M, Zouhair A (August 2011). "Pure seminoma: a review and update". Radiat Oncol. 6: 90. doi:10.1186/1748-717X-6-90. PMC 3163197. PMID 21819630.
- ↑ Paly, Jonathan J.; Efstathiou, Jason A.; Hedgire, Sandeep S.; Chung, Peter W.M.; O’Malley, Martin; Shah, Anand; Bekelman, Justin E.; Harisinghani, Mukesh; Shipley, William U.; Zietman, Anthony L.; Beard, Clair (2013). "Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields". Radiotherapy and Oncology. 106 (1): 64–68. doi:10.1016/j.radonc.2012.12.002. ISSN 0167-8140.